Washington – A group of labor unions are asking a federal court for an emergency order to stop Elon Musk 's Department of Government Efficiency from accessing the sensitive Social Security data ...

In a report released on March 5, Seiji Wakao from J.P. Morgan maintained a Hold rating on Eisai Co (ESALF – Research Report), with a price target of Yen4,200.00. The company’s shares closed ...

Japanese pharma group Eisai says it is battling a ransomware attack that was launched last weekend and has resulted in some of its servers becoming encrypted. The attack has affected servers both ...

INDIANAPOLIS (Thursday, March 6, 2025) – Two-time NTT INDYCAR SERIES champion and back-to-back winner of the Indianapolis 500 presented by Gainbridge Josef Newgarden celebrated Southwest Airlines’ ...

TOKYO and CAMBRIDGE, Mass., Mar 4, 2025 - (JCN Newswire) - - Eisai Co., Ltd. and Biogen Inc. announced today that the Therapeutic Goods Administration (TGA) of Australia has confirmed the initial ...

Australia’s Therapeutic Goods Administration (TGA) has once again decided against approving Eisai Australia Pty Ltd.’s amyloid beta binder, Leqembi (lecanemab), for treating patients with mild ...

(MENAFN- JCN NewsWire) "Fatigue Recovery While You Sleep!" Eisai to Launch Designated Quasi-Drug Drink "Chocola BB Nightwell" - Easy-To-Drink Grapefruit Flavor Containing Herbal Medicines and ...

The European Union’s medicines regulator on Friday reiterated its positive recommendation for Eisai and Biogen’s Alzheimer’s drug, Leqembi, after concluding a safety review. The European ...

Biogen and Eisai said the European Medicines Agency's Committee for Medicinal Products for Human Use has reaffirmed its recommended approval of their Alzheimer's drug Leqembi. The companies on ...

Feb 28 (Reuters) - The European Union's medicines regulator on Friday reiterated its positive recommendation for Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab Alzheimer's drug ...

Eisai Co., Ltd. has entered into a license agreement granting the exclusive development and distribution rights for the fibroblast growth factor (FGF) receptor selective tyrosine kinase inhibitor ...

Amid Eisai’s efforts to capitalize on a potential growth surge for its Alzheimer’s disease med Leqembi, the Japanese drugmaker is reworking parts of its operations in the U.S. Eisai plans to ...